¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ras gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® gene ÇÑ±Û À¯ÀüÀÚ
¼³¸í   
  À¯ÀüÀڴ ±æ°Ô ¶ì¸¦ Çü¼ºÇÑ DNAºÐÀÚÀÇ ÀϺκÐÀ¸·Î ÇÑ °¡Áö ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °®Ãá ±â´ÉÀûÀΠ´ÜÀ§ÀÌ´Ù. ¿¹¸¦ µé¾î Àν¶¸°À̶ó´Â ¹°ÁúÀÇ À¯ÀüÀÚ¶ó°í Çϸ頻ç¶÷ÀÇ ¼¼Æ÷³»¿¡ Àִ ±ä DNA ºÐÀÚ Áß¿¡¼­ Àν¶¸°À̶ó´Â ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °¡Áö°í Àִ ÇÑ ºÎºÐÀ» °¡¸®Å°´Â ¸»ÀÌ´Ù. °íÀüÀûÀΠ»ý¹°Çп¡¼­´Â À¯ÀüÀÚ°¡ Ç¥ÇöÇüÀ» °áÁ¤Çϰųª ÁöÁ¤Çϴ ¿°»öüÀÇ ÀϺκÐÀ̶ó°í Á¤ÀǵǾúÁö¸¸, ¿À´Ã³¯¿¡´Â À¯ÀüÀÚ¿¡ ´ëÇØ¼­ ºÐÀÚÀû Á¤Àǰ¡ Á¦¾ÈµÇ°í ÀÖÀ¸¸ç ±× Á¤ÀǴ ÇϳªÀÇ À¯ÀüÀڴ ÇϳªÀÇ È¿¼Ò¸¦ °áÁ¤ ¶Ç´Â ¾ÏȣȭÇϴ À¯Àü¹°ÁúÀÇ ÀϺκÐÀ̶ó´Â °³³äÀ¸·Î À̰ÍÀÌ À̸¥¹Ù 1°³ÀÇ À¯ÀüÀÚ 1°³ È¿¼Ò°¡¼³(one gene-one enzyme hypothesis)ÀÌ´Ù. Áï 1°³ÀÇ À¯ÀüÀڴ 1°³ÀÇ È¿¼Ò¸¦ Á¦ÀÛÇϴµ¥ ÇÊ¿äÇÑ À¯ÀüÁ¤º¸¸¦ °¡Áø´Ù´Â °ÍÀÌ´Ù. ÇöÀç ÀÌ °¡¼³ÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Ù.
¿µ¹® gene therapy ÇÑ±Û À¯ÀüÀÚ¿ä¹ý
¼³¸í   
  À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇϴ ´ÜÀÏÀ¯ÀüÀڠȤÀº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼­ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇϴ °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇϴ ġ·á·Î¼­ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °­ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ È¯ÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇϴ ¸ñÀûÀ¸·Î ¾²ÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gene
    À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • regulator gene
    Á¶ÀýÀ¯ÀüÀÚ
  • structural gene
    ±¸Á¶À¯ÀüÀÚ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • supressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gene transfection
    1.À¯ÀüÀÚÀü´Þ°¨¿°, 2.À¯ÀüÀÚÇÙ³»ÁÖÀÔ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ras gene
    ras À¯ÀüÀÚ(¡­ë¶îîí­)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ras protein
    ras ´Ü¹é(¡­Ó±ÛÜ)
  • C-fos gene
    ¾¾-Æ÷½ºÀ¯ÀüÀÚ(ë¶îîí­)
  • C-jun gene
    ¾¾-ÁØ À¯ÀüÀÚ(ë¶îîí­)
  • DNA mediated gene transfer
    DNA ¸Å°³¼ºÀ¯ÀüÀÚÀüÀÌ
  • DP gene
    DPÀ¯ÀüÀÚ
  • DQ gene
    DQÀ¯ÀüÀÚ
  • DR gene
    DRÀ¯ÀüÀÚ
  • Gag gene
    gag À¯Àü(ÀÎ)ÀÚ
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • Hfr mediated gene transfer
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷¸Å°³ À¯ÀüÀÚÀüÀÌ
  • Onc gene
    Onc À¯ÀüÀÚ
  • Src gene
    Src À¯Àü(ÀÎ)ÀÚ
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ras gene
    ras À¯ÀüÀÚ(¡­ë¶îîí­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ras protein
    ras ´Ü¹é(¡­Ó±ÛÜ)
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • atk gene
    atk À¯ÀüÀÚ(¡­ë¶îîí­)
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • bcg gene
    bcg À¯ÀüÀÚ(¡­ë¶îîí­)
  • bcl gene
    bcl À¯ÀüÀÚ
  • bcr-c-abl gene
    bcr-c-abl À¯ÀüÀÚ
  • beta-globin gene
    º£Å¸±×·ÎºóÀ¯ÀüÀÚ(¡­ë¶îîí­)
  • c4a gene
    C4A À¯ÀüÀÚ (¡­ë¶îîí­)
  • calcitonin-gene related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • complementary gene
    º¸Á·À¯ÀüÀÚ(ÜÍðëë¶îîí­), º¸Ã¼À¯ÀüÀÚ.
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº(ïÈõºàõë¶îîí­ñøý¦ÏØ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] [µ¹¿¬]º¯ÀÌÀ¯ÀüÀÚ
  • Autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] »ó¿°»öüÀ¯ÀüÀÚ
  • Gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¼º¿°»öüÀ¯ÀüÀÚ
  • Recessive autosomal gene
    ¿­¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿­¼º»ó¿°»öüÀ¯ÀüÀÚ
  • Recessive gonosomal gene
    ¿­¼º¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿­¼º¼º¿°»öüÀ¯ÀüÀÚ
  • Dominant autosomal gene
    ¿ì¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿ì¼º»ó¿°»öüÀ¯ÀüÀÚ
  • Dominant gonosomal gene
    ¿ì¼º¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿ì¼º¼º¿°»öüÀ¯ÀüÀÚ
  • Lethal gene
    Ä¡»çÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] Ä¡»çÀ¯ÀüÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ras gene
    ras À¯ÀüÀÚ(ë¶îîí­)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • abl gene
    abl À¯ÀüÀÚ(ë¶îîí­)
  • cancer gene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • constitutive gene
    ±¸¼ºÀ¯ÀüÀÚ(ϰà÷ë¶îîí­)
  • controlling gene
    Á¶Àý À¯ÀüÀÚ(ðàï½ë¶îîí­)
  • c-src gene
    c-src À¯ÀüÀÚ(ë¶îîí­)
  • cytoplasmic gene
    ¼¼Æ÷Áú À¯ÀüÀÚ(á¬øàòõë¶îîí­)
  • D gene
    D À¯ÀüÀÚ(ë¶îîí­)
  • dispensable gene
    ºñÇʼö À¯ÀüÀÚ(Þªù±âÎë¶îîí­) (ÔÒ) nonessential gene
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ(éÐàõë¶îîí­)
  • duplicate gene
    º¹»ç À¯ÀüÀÚ(ÜÜÞÐë¶îîí­)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gene
    À¯ÀüÀÎÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RAS   1) Reticular Activating(Activation) System
  2) Renal Artery Stenosis
RAS rapid atrial stimulation; recurrent aphthous stomatitis; reflex activating stimulus; reliability, av...
ras retrovirus-associated DNA sequence
CGRP Calcitonin Gene Related Peptide(Protein)
CGRPs Calcitonin Gene-Related Products
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Ras GAP Ras GTPase activating protein
Ras p21(ras
KSR Kinase Suppressor of Ras
GAP RAS-GTPase activating protein
MAPK RAS-mitogen-activated protein kinase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Ras.
    ¹®Áö¸£±â
    L. rasuraeÀÇ ¾àÀÚ
  • allelic gene
    ´ë¸³ À¯ÀüÀÚ
  • C-jun gene
    ¾¾-ÁØ À¯ÀüÀÚ
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ
  • duplicate gene
    Áߺ¹ À¯Àü ÀÎÀÚ
  • exaggeration gene
    °­Á¶ À¯ÀüÀÚ
  • fcc gene
    FCC À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
p21(ras) farnesyl-protein transferase <enzyme> Transfers the farnesyl moiety from farnesyl pyrophosphate to a cysteine in p21(ras) proteins; composed of an alpha and a beta subunit
Registry number: EC 2.5.1.-
Synonym: farnesyl-protein transferase p21(ras), ras p21 farnesyl-protein transferase, protein-cysteine farnesyltransferase, pc farnesyltransferase, protein farnesyltransferase, p21(ras) farnesyltransferase, farnesyl-protein transferase-alpha, farnesyl-protein transferase-beta, ft alpha, ft beta, caax farnesyltransferase, ftase enzyme
(26 Jun 1999)
ras <oncogene> One of a family of oncogenes, first identified as transforming genes of Harvey and Kirsten murine sarcoma viruses. (Name from rat sarcoma because Harvey virus, though a mouse virus, obtained its transforming gene during passage in a rat). Transforming protein coded is p21ras, a GTP-binding protein with GTPase activity, that resembles regulatory G-proteins.
(18 Nov 1997)
ras protein geranylgeranyltransferase <enzyme> Mammalian enzyme transfers geranylgeranyl groups to a cysteine residue fourth from the c-terminal group of a p21 ras protein, prefers leucine at the cooh terminus; see also rhoa geranylgeranyltransferase and protein geranylgeranyltransferase
Registry number: EC 2.5.1.-
Synonym: geranylgeranyltransferase ras protein, ras protein gg transferase, ggtase I, caax geranylgeranyl transferase
(26 Jun 1999)
ras proteins Small GTP-binding proteins encoded by ras genes (genes, ras) that play a critical role in normal cellular growth, differentiation, and development, and have the potential for malignant transformation. Two of the major ras proteins include the normal cellular form, proto-oncogene protein p21(ras), and the malignant form, oncogene protein p21(ras).
(12 Dec 1998)
genes, ras Family of retrovirus-associated DNA sequences (ras) originally isolated from harvey (h-ras, ha-ras, rash) and kirsten (k-ras, ki-ras, rask) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both h-ras and k-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related n-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
(12 Dec 1998)
proto-oncogene protein p21(ras) Cellular protein encoded by the c-ras genes. The protein has GTPase activity and is involved in transmembrane signal transduction as a guanine nucleotide binding protein. Elevated levels of p21 c-ras have been associated with neoplasia.
(12 Dec 1998)
h-ras <oncogene> A point-mutated proto-oncogene that is found in melanoma and in carcinoma of colon, lung and pancreatic tissue.
(10 Oct 1997)
oncogene protein p21(ras) Transforming protein encoded by ras oncogenes. Point mutations in the cellular ras gene (c-ras) can also result in a mutant p21 protein that can transform mammalian cells. Oncogene protein p21(ras) has been directly implicated in human neoplasms, perhaps accounting for as much as 15-20% of all human tumours.
(12 Dec 1998)
k-ras <oncogene> A proto-oncogene that has point mutations and is associated with melanoma, thyroid carcinoma, and acute myelogenous and lymphoblastic leukaemia.
(09 Oct 1997)
allelic gene See: allele, dominance of traits.
(05 Mar 2000)
antibiotic resistance gene Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it.
(09 Oct 1997)
autosomal gene A gene located on any chromosome other than the sex chromosomes (X or Y).
(05 Mar 2000)
bicoid gene A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster.
(09 Oct 1997)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • RAS
    reliability;availability & serviceability ½Å·Úµµ;À̿밡´Éµµ;º¸¼ö °¡´Éµµ(ÄÄÇ»ÅÍ ´É·Â Æò°¡ÀÇ ÁÖ¿ä¼Ò)
  • Ir gene
    (»ýÈ­)IrÀ¯ÀüÀÚ(¸é¿ª ÀÀ´ä À¯ÀüÀÚ)
  • coat gene
    ÇǸ·À¯ÀüÀÚ
  • dominant gene
    (»ý)¿ì¼º À¯ÀüÀÚ
  • gene
    À¯Àü(ÀÎ)ÀÚ
  • gene bank
    À¯ÀüÀÚ ÀºÇà(À¯Àü ¹°ÁúÀ» »ýÁ¸½ÃŲ »óÅ·Πº¸Á¸ÇÏ´Â ½Ã¼³
  • gene deletion
    À¯ÀüÀÚ »èÁ¦(ºÒÇÊ¿äÇÑ À¯ÀüÀÚÀÇ Á¦°Å)
  • gene expression
    À¯ÀüÀÚ ¹ßÇö(À¯ÀüÀÚ Á¤º¸°¡ ƯÁ¤ ÇüÁú·Î¼­ ³ªÅ¸³ª±â)
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ºüÁ®ÀÖ´Â À¯ÀüÀÚ¸¦ »ðÀÔÇϱâ)
  • gene manipulation
    À¯ÀüÀÚ Á¶ÀÛ(ÀÎÀ§ÀûÀ¸·Î À¯ÀüÀÚ¸¦ ¿Å±â°Å³ª ¿°»öü µîÀ» º¯È­½Ã۱â)
  • gene mapping
    À¯ÀüÀÚ Áöµµ(¿°»öü»óÀÇ À¯ÀüÀÚ ÀÚ¸®¸¦ °áÁ¤Çϱâ)
  • gene pool
    À¯ÀüÀÚ Ç®;À¯ÀüÀÚ °ø±Þ¿ø(¸àµ¨ Áý´ÜÀ» ±¸¼ºÇÏ´Â ¸ðµç °³Ã¼°¡ °¡Áö°í ÀÖ´Â À¯ÀüÀÚ Àüü)
  • gene therapy
    À¯ÀüÀÚ ¿ä¹ý(°á¼ÕµÈ À¯ÀüÀÚ¸¦ º¸ÃæÇÏ¿© À¯Àüº´À» °íÄ¡´Â ¿ä¹ý)
  • nif gene
    (»ýÈ­)Áú¼Ò °íÁ¤¿¡ °ü¿©ÇÏ´Â À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á